Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CEO Sells $4,580,221.32 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 85,788 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the transaction, the chief executive officer now directly owns 5,771,787 shares of the company’s stock, valued at $308,155,707.93. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Stock Performance

Shares of TEM opened at $51.40 on Monday. The business’s 50 day moving average is $44.36 and its 200 day moving average is $47.77. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the stock. First Horizon Advisors Inc. bought a new position in shares of Tempus AI during the third quarter worth $30,000. Geode Capital Management LLC boosted its holdings in shares of Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after purchasing an additional 539 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Tempus AI during the fourth quarter valued at about $67,000. Vestor Capital LLC bought a new stake in shares of Tempus AI in the third quarter worth about $153,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Tempus AI by 10.2% in the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after buying an additional 2,765 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Piper Sandler restated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Bank of America boosted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Guggenheim began coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. Finally, Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and upped their price target for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $56.36.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.